Tenderwize
Retour à la recherche

Non-exclusive agreement for fremanezumab medicines

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Mar 31, 2028 · 581 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Vereinbarungen über Arzneimittel mit dem Wirkstoff Fremanezumab (ATC-Code: N02CD03) im Wege eines Open-House-Modells

52/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

52 / 100

Complexité

58 / 100

Facteurs de risque

The exact submission instructions and all deadlines are said to be contained in project-room documents that were not pr...

Only pharmaceutical undertakings within the meaning of section 4(18) AMG may participate, and local representatives qua...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Mar 2028
  • Supply of pharmaceutical products containing the active substance fremanezumab (ATC code N02CD03).
  • Open-House participation model for non-exclusive contractual arrangements.
Afficher le résumé complet

This is an Open-House supply arrangement for pharmaceutical products containing fremanezumab (ATC N02CD03), led by AOK PLUS. It is non-exclusive, open to all interested pharmaceutical companies that meet and accept the participation conditions. No individual negotiations or guaranteed minimum purchase volumes are provided. Participation documents must be obtained via DTVP after access approval, and participation requests are submitted electronically through the portal communication function. The arrangement runs until 31 March 2028 at the latest. The notice contains several technical/formal fields that are stated to have no substantive legal meaning for this Open-House procedure.

Risques

The exact submission instructions and all deadlines are said to be contained in project-room documents that were not pr...

Only pharmaceutical undertakings within the meaning of section 4(18) AMG may participate, and local representatives qua...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Applicant must be a pharmaceutical company within the meaning of the notice.

Eligibility

  • The declaration on non-existence of exclusion grounds must be completed and submitted.

Administrative

  • Participation conditions in the documents must be accepted.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive agreement for fremanezumab medicines

Open-House supply arrangement for medicines containing fremanezumab (ATC N02CD03). The lot is described as a non-exclusive agreement open to all interested pharmaceutical companies that satisfy the participation conditions. No minimum purchase quantity is guaranteed and demand is stated to be unknown. Place of performance is Dresden, Germany, with broader reference to Germany / Saxony / Thuringia in the notice text.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Mar 2026 - Mar 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Mar 31, 2028

Détails de la procédure

Date de publication
05 Feb 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
88189-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30